DENVER, Dec. 13 /PRNewswire/ -- Embla Systems, a leader in the field of sleep diagnostic software and equipment announced today the signing of an exclusive agreement with the Beth Israel Deaconess Medical Center (BIDMC) for the distribution of the Cardio Pulmonary Coupling (CPC) technology developed by Drs. Robert Thomas, Ary Goldberger, C-K. Peng, and Mr. Joseph Mietus.
CPC technology represents a breakthrough in how sleep can be visualized, by presenting a simple and accurate picture of sleep oscillations and interactions instead of the tedious manual sleep stage scoring and counting of respiratory events that has been the standard for the last 40 years. The analysis has been validated using over 10,000 sleep studies. "The CPC technology is not a sleep-stage or respiratory event detector but [it] does provide a dynamic measure of sleep state-modulated cardio-pulmonary interactions," says Dr. Robert Thomas. "As the technique is automated, inter-scorer reliability is eliminated as a problem. The technique can track dynamic sleep physiology, and provide a unique ambulatory measure of sleep quality."
"With the anticipated introduction of reimbursement for home testing, the integration of this technology into Embla's existing product line confirms our dominant position in this market place," said David Baker, President and CEO of Embla. "In addition, the technology will allow us to develop very low cost and reliable diagnostic tools to assist clinicians in diagnosing the presence of sleep apnea among the huge population of undiagnosed people who suffer from this condition, while allowing an unprecedented method to monitor treatment effects on sleep quality and respiratory dynamics in the 13 million or so users of CPAP machines in the US alone".
The CPC technology will give physicians the "Sleep Health" of a patient and to evaluate if the patient has Obstructive, Central or Complex Sleep Apnea. The clinical significance of such a simple and low cost test is that it will accelerate necessary medical assistance to those patients in need of diagnosis for sleep disorder breathing at a fraction of today's current cost. Moreover, clinicians will benefit from the phenotyping capabilities of the technology to enhance diagnostic accuracy of non-obstructive forms of sleep disorder breathing (including heart failure patients), recommend appropriate treatment, and evaluate treatment efficacy. Over the next 12 to 18 months Embla will be developing the technology into their existing laboratory based Polysomnography (PSG) equipment and their portable home monitoring equipment.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School, and consistently ranks among the top four in National Institutes of Health funding among independent hospitals nationwide. BIDMC is clinically affiliated with the Joslin Diabetes Center and is a research partner of Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox.
For more information, please visit http://www.bidmc.harvard.edu.
Embla's alliance with major academic institutions for intellectual technology ensures attaining the business and strategic goals of the company to advance the science of sleep medicine and to bring evidence based medicine into general practice.
Embla Systems is headquartered in Denver Colorado and is a leading provider of Sleep Diagnostic Equipment in the world. For more information, please visit http://www.embla.com
Embla Systems is a part of Flaga Group, a public company listed on the Icelandic Stock Exchange.
For more information, please visit http://www.flagagroup.com
|SOURCE Embla Systems|
Copyright©2007 PR Newswire.
All rights reserved